NCT07155044 is a clinical trial of NAC in UTUC, sponsored by Changhai Hospital.

Who is sponsoring NCT07155044?

NCT07155044 is sponsored by Changhai Hospital.

What drugs are being tested in NCT07155044?

Interventions in NCT07155044: NAC.

What condition does NCT07155044 study?

NCT07155044 studies UTUC, UC (Urothelial Cancer).

Is NCT07155044 still recruiting?

NCT07155044 is currently active, enrolled. Last updated 4 September 2025.

Last reviewed 2025-09-04 · How we verify

NCT07155044

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma

Active, enrolled Last updated 4 September 2025

What this trial tests

trial testing NAC in UTUC in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 May 2024

Primary endpoint
15 May 2027

15 May 2029

Quick facts

Lead sponsor	Changhai Hospital
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	120
Start date	15 May 2024
Primary completion	15 May 2027
Estimated completion	15 May 2029
Sites	1 location across China

Drugs / interventions tested

NAC — full drug profile →

Conditions studied

UTUC — all drugs for UTUC →
UC (Urothelial Cancer) — all drugs for UC (Urothelial Cancer) →

Sponsor

Changhai Hospital

Who can join

18 and older, any sex, with UTUC or UC (Urothelial Cancer). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label, non-randomized controlled trial comparing the efficacy and safety of neoadjuvant chemotherapy (NAC) followed by radical surgery versus upfront radical surgery alone in patients with high-risk, non-metastatic upper tract urothelial carcinoma (UTUC). The study aims to answer the following key questions: Does NAC improve pathologic response rates (defined as downstaging to \<ypT2N0) compared to immediate surgery? What is the rate of pathologic complete response (pCR; ypT0N0) in the NAC group? How do the two treatment strategies compare in terms of overall survival, cancer-specific survival, and recurrence-free survival? What is the safety and tolerability profile of NAC using gemcitabine and cisplatin in this patient population? Eligible participants will be assigned to either the NAC-plus-surgery group or the surgery-only group based on clinical evaluation and patient preference. The study will also explore potential biomarkers (e.g., chromosomal instability in liquid biopsies) for predicting treatment response. Key Eligibility Criteria: Adults with histologically confirmed high-risk UTUC Clinical stage ≤N1 M0 Adequate renal function (GFR ≥45 mL/min) and ECOG performance status 0-1 Primary Outcome: Pathologic response rate (proportion of patients with \<ypT2N0)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of NAC

Trials testing the same drug.

NCT07227649 — NAC-REPAIR for Post-surgical Pain · Phase 2 · not yet recruiting
NCT05509153 — A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers · Phase 2 · recruiting
NCT06367413 — Effects of Protein and NAC Co-ingestion on Skeletal Muscle Recovery · NA · recruiting
NCT06252519 — Pharmacokinetic Profile of N-Acetyl Cysteine · NA · completed
NCT04693949 — Effect of Nano-structured Alumina Coating on the Bond Strength of Zirconia Resin-bonded Fixed Dental Prostheses · NA · unknown

Other recruiting trials for UTUC

Currently open trials in the same condition.

NCT06993779 — Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Upper Tract Urothelial C · active not recruiting
NCT06991868 — A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Mi · recruiting
NCT06167057 — POST URS Chemotherapy Instillation · NA · recruiting

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07155044 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 4 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07155044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing